Pharmacokinetics of chlorzoxazone in rats with diabetes: Induction of CYP2E1 on 6-hydroxychlorzoxazone formation

Journal of Pharmaceutical Sciences

Volumn 95, Issue 11, 2006, Pages 2452-2462

  Baek, Hye W ^a   Bae, Soo K ^b   Lee, Myung G ^b   Sohn, Young T ^a  

^a Duksung Women's University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

CYP enzymes; CYP2E1; CZX and OH CZX; Disease state; Intrinsic clearance; Metabolism; Pharmacokinetics; Protein binding; Rat model of diabetes induced by alloxan (DMIA) or streptozotocin (DMIS); Rats

Indexed keywords

6 HYDROXYCHLORZOXAZONE; ALLOXAN; CHLORZOXAZONE; CYTOCHROME P450 2E1; MESSENGER RNA; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME INDUCTION; KIDNEY CLEARANCE; LIVER BLOOD FLOW; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MICROSOME; NONHUMAN; PROTEIN EXPRESSION; RAT;

EID: 33750914445     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20698     Document Type: Article

References (32)

1. Chen L, Yang CS. 1996. Effects of cytochrome P450 2E1 modulators on the pharmacokinetics of chlorzoxazone and 6-hydroxychlorzoxazone in rats. Life Sci 58:1575-1585.
2. Conney AH, Burns JJ. 1960. Physiological disposition and metabolic fate of chlorzoxazone (Paraflex) in man. J Pharmacol Exp Ther 128:340-343.
3. Desiraju RK, Renzi NL, Jr., Nayak RK, Ng KT. 1983. Pharmacokinetics of chlorzoxazone in humans. J Phram Sci 72:991-994.
4. Rockich K, Blouin R. 1999. Effect of the acute-phase response on the pharmacokinetics of chlorzoxazone and cytochrome P-450 2E1 in vitro activity in rats. Drug Metab Dispos 27:1074-1077.
5. Kim YG, Cho MK, Kwon JW, Kim SG, Chung SJ, Shim CK, Lee MG. 2002. Effects of cysteine on the pharmacokinetics of intravenous chlorzoxazone in rats with protein-calorie malnutrition. Biopharm Drug Dispos 23:121-129.
6. Ahn CY, Kim EJ, Lee I, Kwon JW, Kim WB, Kim SG, Lee MG. 2003. Effects of glucose on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. J Pharm Sci 92:1604-1613.
7. Chung W-S, Kim EJ, Lee I, Kim SG, Lee MG, Kim SH. 2003. Effects of recombinant human growth hormone on the pharmacokinetics of intravenous chlorzoxazone in rats with acute renal failure induced by uranyl nitrate. Life Sci 73:253-263.
8. Moon YJ, Lee AK, Chung HJ, Kim EJ, Kim SH, Lee DC, Lee I, Kim SG, Lee MG. 2003. Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats. Drug Metab Dispos 31:776-784.
9. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. 1990. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 2E1. Chem Res Toxicol 3:566-573.
10. Carnovale CE, Marinelli RA, Rodriguez-Garay EA. 1986. Bile flow decrease and altered bile composition in streptozotocin-treated rats. Biochem Pharmacol 35:2625-2628.
11. Watkins JB, III, Sherman SE. 1992. Long-term diabetes alters the hepatobiliary clearance of acetoaminophen, bilirubin and digoxin. J Pharmacol Exp Ther 260:1337-1343.
12. Nadai M, Yoshizumi H, Kuzuya T, Hasegawa T, Johno I, Kitazawa S. 1990. Effects of diabetes on disposition and renal handling of cefazolin in rats. Drug Metab Dispos 18:565-570.
13. Park JM, Moon CH, Lee MG. 1996. Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats. Res Commun Mol Pathol Pharmacol 93:343-352.
14. Price VF, Jollow DJ. 1986. Strain differences in susceptibility of normal and diabetic rats to acetaminophen hepatotoxicity. Biochem Pharmacol 35:687-695.
15. Kim YC, Lee AK, Lee JH, Lee I, Lee DC, Kim SH, Kim SG, Lee MG. 2005. Pharmacokinetics of theophylline in diabetes mellitus rats: Induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation. Eur J Pharm Sci 26:114-123.
16. Kim SH, Kim WB, Lee MG. 1998, Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with alloxan-induced diabetes mellitus. Biopharm Drug Dispos 19:303-308.
17. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
18. Frye RF, Stiff DD. 1996. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. J Chromatogr B 686:291-296.
19. Duggleby RG. 1995. Analysis of enzyme progress curves by nonlinear regression. Methods Enzymol 249:61-90.
20. Liu PT, Ioannides C, Shavila J, Symons AM, Parke DV. 1993. Effects of ether anaesthesia and fasting on various cytochromes P450 of rat liver and kidney. Biochem Pharmacol 45:871-877.
21. Shim HJ, Lee EJ, Kim SH, Kim SH, Yoo M, Kwon JW, Kim WB, Lee MG. 2000. Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 21:285-291.
22. Chiou WL. 1978. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-549.
23. Gibaldi M, Perrier D. 1982. Pharmacokinetics. (2nd edn) New York: Marcel-Dekker, Inc.
24. Kim SH, Choi YM, Lee MG. 1993. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 21:1-17.
25. Chiou WL. 1979. New calculation method for mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci 68: 1067-1069.
26. Eatman FB, Colburn WA, Boxenbaum HG, Posmanter HN, Weinfeld RE, Ronfeld R, Weissman L, Moore JD, Gibaldi M, Kaplan SA. 1977. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 5:481-494.
27. Chiou WL. 1980. New calculation method of mean total body clearance of drugs and its application to rational regimens. J Pharm Sci 69:90-91.
28. Li L, Zhang Y. 1998. Changes of CYP2E1 activity in diabetic rat model. Yao Xue Xue Bao 33:891-895.
29. Wilkinson GR, Shand DG. 1975. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
30. Sato H, Terasaki T, Okumura K, Tsuji A. 1991. Effect of receptor up-regulation on insulin pharmacokinetics in streptozotocin-treated diabetic rats. Pharm Res 8:563-569.
31. Bae SK, Yang SH, Lee SJ, Kwon JW, Kim WB, Lee DC, Lee MG. 2005. Pharmacokinetic changes of DA-7867, a new oxazolidinone, after intravenous and oral administration to rats with short-term and long-term diabetes mellitus induced by streptozotocin. Eur J Pharm Sci 25:337-345.
32. Lee MG, Chiou WL. 1983. Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623-640.